Novartis was criticised for making inflated claims about its drug, Femara
(Keystone Archive)
The United States health authorities have ordered the Swiss healthcare giant, Novartis, to pull an advertisement from a medical journal because it fails to conform to advertising regulations.
In a letter to Novartis, the US Food and Drug Administration (FDA) said an advertisement for the recently approved hormone drug, "Femara", claimed the medication could treat illnesses for which it was not certified.
It said the advertisement, which appeared in the medical journal, "Oncology", failed to explain clearly the treatment for which "Femara" had been certified and that it did not contain the required information about side-effects.
It said this information had also been repeated in a press release of January 11 (web address below).
The FDA said Novartis had claimed that Femara was a pre-operative treatment for reducing the size of chest tumours. However, the drug has been certified only for first-line treatment for advanced breast cancer in post-menopausal women.
Femara was given the green light in the US last month, following a fast-track review by the US food and drug administration. It has since been approved in Europe.
Novartis would only say that it was preparing its response.
All rights reserved. The content of the website by swissinfo.ch is copyrighted. It is intended for private use only. Any other use of the website content beyond the use stipulated above, particularly the distribution, modification, transmission, storage and copying requires prior written consent of swissinfo.ch. Should you be interested in any such use of the website content, please contact us via contact@swissinfo.ch.
As regards the use for private purposes, it is only permitted to use a hyperlink to specific content, and to place it on your own website or a website of third parties. The swissinfo.ch website content may only be embedded in an ad-free environment without any modifications. Specifically applying to all software, folders, data and their content provided for download by the swissinfo.ch website, a basic, non-exclusive and non-transferable license is granted that is restricted to the one-time downloading and saving of said data on private devices. All other rights remain the property of swissinfo.ch. In particular, any sale or commercial use of these data is prohibited.
